Evommune, Inc.
15.70%
4,929,633
2044725
30054Y107
Nov 6, 2025
Nov 14, 2025, 04:30 PM
Reporting Persons (2)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | Other | 15.70% | 4,929,633 | 0 | 4,929,633 |
| LSP 7 Management B.V. | Other | 15.70% | 4,929,633 | 0 | 4,929,633 |
Disclosure Items (7)
Common Stock, $0.0001 par value per share
Evommune, Inc.
1841 Page Mill Road, Palo Alto, CA, 94304
The Schedule 13D is being filed by the following persons (each a "Reporting Person" and, collectively, the "Reporting Persons"): LSP 7 Cooperatieve U.A. ("LSP 7"); and LSP 7 Management B.V. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe (collectively, the "Related Persons").
The business address of each of the Reporting Persons and the Related Persons is c/o LSP, Johannes Vermeerplein 9, 1071 DV Amsterdam, the Netherlands.
The Reporting Persons are principally engaged in the business of investments in securities. The current principal occupation of each of the Related Persons is Partner and Managing Director of EQT Life Sciences (formerly Life Sciences Partners).
During the last five years, none of the Reporting Persons nor any of the Related Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Each of the Reporting Persons is organized under the laws of the Netherlands. Messrs. Kleijwegt and Kuijten are citizens of the Netherlands, and Mr. Rothe is a citizen of Germany.
On September 2, 2021, LSP 7 purchased 10,070,753 shares of the Issuer's Series A Preferred Stock at a purchase price of $1.9363 per share, for aggregate consideration of $19,499,999.04. On December 15, 2022, LSP 7 purchased an additional 5,422,713 shares of the Issuer's Series A Preferred Stock for aggregate consideration of $10,499,999.19. On March 29, 2023, LSP 7 purchased 5,090,000 shares of the Issuer's Series B Preferred Stock at a purchase price of $2.00 per share, for aggregate consideration of $10,180,000.00. On October 31, 2024, LSP 7 purchased 2,863,048 shares of the Issuer's Series C Preferred Stock at a purchase price of $1.59453 per share, for aggregate consideration of $4,565,215.93. On June 27, 2025, LSP 7 purchased an additional 3,721,963 shares of the Issuer's Series C Preferred Stock for aggregate consideration of $5,934,781.67. On October 17, 2025, the Issuer effected a 1-for-8.5180 reverse stock split of the Common Stock. Upon the consummation of the Issuer's initial public offering (the "IPO") on November 7, 2025 (the "Closing Date"), all of LSP 7's preferred stock automatically converted into an aggregate 3,367,133 shares of Common Stock. On the Closing Date, LSP 7 acquired 1,562,500 shares of Common Stock at a purchase price of $16.00 per share, for aggregate consideration of $25,000,000.00. LSP 7 obtained the funds for these transactions through capital contributions from its members.
The ownership information presented herein represents beneficial ownership of Common Stock as of the date hereof, based on 31,483,810 shares of Common Stock outstanding as of the date of this filing. LSP 7 is the record holder of the shares of Common Stock reported herein and is the beneficial owner of approximately 15.7% of the outstanding shares of Common Stock. LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.
Sole power to vote or to direct the vote: 0 Shared power to vote or to direct the vote: 4,929,633 Sole power to dispose or to direct the disposition of: 0 Shared power to dispose or to direct the disposition of: 4,929,633
Except as set forth in this Schedule 13D, during the past 60 days, none of the Reporting Persons nor the Related Persons have effected any transactions in the Common Stock.
None.
Not applicable.
Item 4 above summarizes certain provisions of the Investors' Rights Agreement and the Lock-Up Agreement and is incorporated herein by reference. A copy of each such agreement is attached as an exhibit to this Schedule 13D and is incorporated by reference herein. Except as set forth herein, none of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.
Exhibit 1: Joint Filing Agreement Exhibit 2: Third Amended and Restated Registration Rights Agreement, dated as of October 30, 2024, by and among Evommune, Inc. and the investors party thereto (incorporated by reference to Exhibit 4.2 to the Issuer's Registration Statement on Form S-1 filed with the SEC on October 9, 2025). Exhibit 3: Lock-Up Agreement